Does VEDOLIZUMAB Cause Interstitial lung disease? 104 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 104 reports of Interstitial lung disease have been filed in association with VEDOLIZUMAB (ENTYVIO). This represents 0.1% of all adverse event reports for VEDOLIZUMAB.
104
Reports of Interstitial lung disease with VEDOLIZUMAB
0.1%
of all VEDOLIZUMAB reports
7
Deaths
58
Hospitalizations
How Dangerous Is Interstitial lung disease From VEDOLIZUMAB?
Of the 104 reports, 7 (6.7%) resulted in death, 58 (55.8%) required hospitalization, and 5 (4.8%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
Yes, Interstitial lung disease is listed as a known adverse reaction in the official FDA drug label for VEDOLIZUMAB.
What Other Side Effects Does VEDOLIZUMAB Cause?
Off label use (21,017)
Colitis ulcerative (13,455)
Crohn's disease (9,759)
Drug ineffective (8,424)
Diarrhoea (7,493)
Abdominal pain (6,401)
Fatigue (5,477)
Haematochezia (5,215)
Frequent bowel movements (4,527)
Arthralgia (4,028)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which VEDOLIZUMAB Alternatives Have Lower Interstitial lung disease Risk?
VEDOLIZUMAB vs VELAGLUCERASE ALFA
VEDOLIZUMAB vs VELCADE
VEDOLIZUMAB vs VELETRI
VEDOLIZUMAB vs VELIPARIB
VEDOLIZUMAB vs VEMURAFENIB